William Burns

Mr. William M.
Burns is an Advisor at Healthcare Royalty Management LLC, a Chairman at Molecular Partners, Inc., a Chairman at Molecular Partners AG, an Independent Non-Executive Vice Chairman at Mesoblast Ltd., a Chairman at Vestergaard Frandsen SA, a Chairman at Health Innovation Challenge Fund, a Chairman at Okairos SRL and a Chairman at Vestergaard SARL. He is on the Board of Directors at Mesoblast Ltd. and The Institute of Cancer Research: Royal Cancer Hospital.
Mr. Burns was previously employed as a Member-Governors Board by The Wellcome Trust Ltd., a Chairman by Okairos AG, a Chairman by Biotie Therapies Oy, a Member-Supervisory Board by Crucell NV, a Senior Independent Non-Executive Director by Shire Plc, a Non-Executive Director by Roche Holding AG, a Non-Executive Director by Shire Group Plc, a Senior Independent Director by Shire Pharmaceuticals, Inc., a Non-Executive Director by Chugai Pharmaceutical Co., Ltd., a Chief Executive Officer-Pharmaceuticals Division by Roche Group, a Chief Executive Officer by Roche Pharmaceuticals, Inc., a Chairman by Interpharma, a Chairman by Masters Pharmaceuticals Ltd., and an Advisor by Novo Holdings A/S (Denmark).
He also served on the board at F.
Hoffmann-La Roche Ltd., Genentech, Inc., European Federation of Pharmaceutical Industries & Assns and International Federation of Pharmaceutical Manufacturers.
He received his undergraduate degree from the University of Strathclyde.